VALENCIA, Calif.--(BUSINESS WIRE)--MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter ended March 31, 2009. For the first quarter of 2009, total operating expenses were $57.8 million, compared to $74.1 million for the first quarter of 2008. Research and development (R&D) expenses decreased by $15.6 million to $42.9 million for the first quarter of 2009 compared to the first quarter of 2008. This decrease in R&D expenses as compared to the same period in the prior year was primarily due to decreased costs associated with the clinical development of AFRESA® as well as decreased manufacturing costs associated with raw material purchases. General and administrative (G&A) expenses decreased by $0.7 million to $14.9 million for the first quarter of 2009 compared to the first quarter of 2008.
